Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 443651 in Healthy Volunteers and Cystic Fibrosis
NCT02976519Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) comparing BI 443651 with Placebo (2 arms). Primary endpoint: Treatment-emergent Adverse Events up to 51 days. Started Feb 2017; status: completed.
02
Drugs
BI-443651
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02976519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976519.